<DOC>
	<DOC>NCT02600494</DOC>
	<brief_summary>The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.</brief_summary>
	<brief_title>Clinical Trial Evaluating ITI-007 as a Monotherapy for the Treatment of Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Major male or female subjects of any race, ages 1875 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder experiencing a current major depressive episode Major any subject unable to provide informed consent any female subject who is pregnant or breastfeeding any subject judged to be medically inappropriate for study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>